These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34125434)

  • 1. Targeted CHO cell engineering approaches can reduce HCP-related enzymatic degradation and improve mAb product quality.
    Dovgan T; Golghalyani V; Zurlo F; Hatton D; Lindo V; Turner R; Harris C; Cui T
    Biotechnol Bioeng; 2021 Oct; 118(10):3821-3831. PubMed ID: 34125434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of co-purifying CHO host cell proteins in monoclonal antibody purification process.
    Liu X; Chen Y; Zhao Y; Liu-Compton V; Chen W; Payne G; Lazar AC
    J Pharm Biomed Anal; 2019 Sep; 174():500-508. PubMed ID: 31234041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex secretome engineering enhances recombinant protein production and purity.
    Kol S; Ley D; Wulff T; Decker M; Arnsdorf J; Schoffelen S; Hansen AH; Jensen TL; Gutierrez JM; Chiang AWT; Masson HO; Palsson BO; Voldborg BG; Pedersen LE; Kildegaard HF; Lee GM; Lewis NE
    Nat Commun; 2020 Apr; 11(1):1908. PubMed ID: 32313013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product.
    Bee JS; Tie L; Johnson D; Dimitrova MN; Jusino KC; Afdahl CD
    Biotechnol Prog; 2015; 31(5):1360-9. PubMed ID: 26259961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host cell protein dynamics in recombinant CHO cells: impacts from harvest to purification and beyond.
    Hogwood CE; Bracewell DG; Smales CM
    Bioengineered; 2013; 4(5):288-91. PubMed ID: 23328085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild hypothermic culture conditions affect residual host cell protein composition post-Protein A chromatography.
    Goey CH; Bell D; Kontoravdi C
    MAbs; 2018 Apr; 10(3):476-487. PubMed ID: 29381421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing.
    Valente KN; Lenhoff AM; Lee KH
    Biotechnol Bioeng; 2015 Jun; 112(6):1232-42. PubMed ID: 25502542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.
    Chiu J; Valente KN; Levy NE; Min L; Lenhoff AM; Lee KH
    Biotechnol Bioeng; 2017 May; 114(5):1006-1015. PubMed ID: 27943242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting product association as a mechanism of host-cell protein persistence in bioprocessing.
    Oh YH; Becker ML; Mendola KM; Choe LH; Min L; Lee KH; Yigzaw Y; Seay A; Bill J; Li X; Roush DJ; Cramer SM; Menegatti S; Lenhoff AM
    Biotechnol Bioeng; 2024 Apr; 121(4):1284-1297. PubMed ID: 38240126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted capture of Chinese hamster ovary host cell proteins: Peptide ligand binding by proteomic analysis.
    Lavoie RA; di Fazio A; Williams TI; Carbonell R; Menegatti S
    Biotechnol Bioeng; 2020 Feb; 117(2):438-452. PubMed ID: 31654407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward unbiased identification and comparative quantification of host cell protein impurities by automated iterative LC-MS/MS (HCP-AIMS) for therapeutic protein development.
    Huang Y; Molden R; Hu M; Qiu H; Li N
    J Pharm Biomed Anal; 2021 Jun; 200():114069. PubMed ID: 33901758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-directed engineering of "difficult-to-express" monoclonal antibody production by Chinese hamster ovary cells.
    Pybus LP; Dean G; West NR; Smith A; Daramola O; Field R; Wilkinson SJ; James DC
    Biotechnol Bioeng; 2014 Feb; 111(2):372-85. PubMed ID: 24081924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of CHO host-cell proteins in monoclonal antibody bioprocessing.
    Oh YH; Mendola KM; Choe LH; Min L; Lavoie AR; Sripada SA; Williams TI; Lee KH; Yigzaw Y; Seay A; Bill J; Li X; Roush DJ; Cramer SM; Menegatti S; Lenhoff AM
    Biotechnol Bioeng; 2024 Jan; 121(1):291-305. PubMed ID: 37877536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin D: Removal strategy on protein A chromatography, near real time monitoring and characterisation during monoclonal antibody production.
    Cui T; Chi B; Heidbrink Thompson J; Kasali T; Sellick C; Turner R
    J Biotechnol; 2019 Nov; 305():51-60. PubMed ID: 31442501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of proteomic methods for CHO host cell protein characterization in biopharmaceutical manufacturing.
    Valente KN; Levy NE; Lee KH; Lenhoff AM
    Curr Opin Biotechnol; 2018 Oct; 53():144-150. PubMed ID: 29414072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to characterize host cell proteins associated with therapeutic monoclonal antibodies.
    Thomson AS; Mai S; Byrne MP
    Biotechnol Bioeng; 2017 Jun; 114(6):1208-1214. PubMed ID: 28112396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement and control of host cell proteins (HCPs) in CHO cell bioprocesses.
    Hogwood CE; Bracewell DG; Smales CM
    Curr Opin Biotechnol; 2014 Dec; 30():153-60. PubMed ID: 25032907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer-mediated flocculation of transient CHO cultures as a simple, high throughput method to facilitate antibody discovery.
    Schmitt MG; Rajendra Y; Hougland MD; Boyles JS; Barnard GC
    Biotechnol Prog; 2017 Sep; 33(5):1393-1400. PubMed ID: 28722325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering.
    Glinšek K; Bozovičar K; Bratkovič T
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for addressing host cell protein impurities in biopharmaceutical product development.
    Tuameh A; Harding SE; Darton NJ
    Biotechnol J; 2023 Mar; 18(3):e2200115. PubMed ID: 36427352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.